Oxford BioMedica secures $50 million loan facility with Oberland Capital to support the Group’s growth ambitions
Oxford, UK – 1 May 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford BioMedica” or the “Group”) a leading gene and cell therapy Group, today announces that it has secured a $50 million loan facility from a subsidiary of Oberland… Read More